Article

Sinusitis and upper respiratory tract diseases may increase the risk for rheumatoid arthritis


 

Key clinical point: Sinusitis, pharyngitis, and acute respiratory burden all raised the likelihood of developing rheumatoid arthritis (RA).

Major finding: Acute sinusitis (odds ratio [OR], 1.61; 95% CI, 1.05-2.45), chronic sinusitis (OR, 2.16; 95% CI, 1.39-3.35), asthma (OR, 1.39; 95% CI, 1.03-1.87), and burden of acute respiratory tract disease during the preindex exposure period (OR, 1.30 per 10 codes; 95% CI, 1.08-1.55) were associated with an elevated risk for RA. Acute pharyngitis was associated with seronegative RA (OR, 1.68; 95% CI, 1.02-2.74), whereas chronic rhinitis/pharyngitis was associated with seropositive RA (OR, 2.46; 95% CI, 1.01-5.99).

Study details: This was a case-control study involving 741 patients with RA matched with 2,223 healthy controls.

Disclosures: The National Institute of Arthritis and Musculoskeletal and Skin Diseases and Rheumatology Research Foundation funded this research. No conflict of interests was reported.

Source: Kronzer VL et al. J Rheumatol. 2021 Oct 15. doi: 10.3899/jrheum.210580 .

Recommended Reading

Tofacitinib postmarketing trial data shed light on JAK inhibitor risks
MDedge Rheumatology
Long-term glucocorticoids in RA linked to increased cardiovascular risk
MDedge Rheumatology
Low-dose rituximab may keep RA disease activity low in responders
MDedge Rheumatology
No risk of increased flare after 2 doses of COVID-19 vaccination in RA
MDedge Rheumatology
RA: bDMARD monotherapy may accelerate radiographic progression of preexisting distal hand osteoarthritis
MDedge Rheumatology
Baricitinib demonstrates consistent long-term safety profile in RA
MDedge Rheumatology
T-helper cell derangements tied to atrial fibrillation in RA
MDedge Rheumatology
Certolizumab seems effective as monotherapy in RA patients with failure to csDMARDs
MDedge Rheumatology
Obesity, depression, anxiety, and illness beliefs influence remission, pain, and fatigue in RA
MDedge Rheumatology
Similar long-term safety/tolerability of filgotinib 100 mg and 200 mg in moderate-to-severe RA
MDedge Rheumatology